This page summarizes information about the clinical trials that support investigation of both approved and experimental medicines. This information includes information about the interventions and their sponsoring organizations. Note that these data are derived from ClinicalTrials.gov, with information corrected and disambiguated to convey more accurate detail about these trials. Phase 4 trials are currently excluded on this page by default, as this data will be analyzed separately at a later date.
Trials with Experimental APIs
Top 5 (by most trials)
platelet-rich plasma (370) COVID-19 convalescent plasma (179) platelet rich fibrin (94) human milk (88) incomplete freund's adjuvant (58)Trials with Approved APIs
Top 5 (by most trials)
rimabotulinumtoxinB (429) immune globulin (human) (349) onabotulinumtoxinA (228) human choriogonadotropin alfa (169) albumin (Human) (152)Trials with Unapproved APIs
Top 5 (by most trials)
whole blood (24)APIs in Phase 1
Top 5 (by most trials)
platelet-rich plasma (89) rimabotulinumtoxinB (57) onabotulinumtoxinA (46) COVID-19 convalescent plasma (38) immune globulin (human) (36)APIs in Phase 2
Top 5 (by most trials)
rimabotulinumtoxinB (305) immune globulin (human) (269) onabotulinumtoxinA (136) platelet-rich plasma (131) pegaspargase (112)APIs in Phase 3
Top 5 (by most trials)
immune globulin (human) (196) rimabotulinumtoxinB (165) onabotulinumtoxinA (86) platelet-rich plasma (69) human choriogonadotropin alfa (55)Phase 1 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (100) Mayo Clinic (34) National Institutes of Health (NIH) (25) Amgen (18) Harvard University (15)Phase 2 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (128) Grifols (48) Allergan (47) National Institutes of Health (NIH) (40) Baxalta (28)Phase 3 Sponsors
Top 5 (by most trials)
Allergan (59) National Cancer Institute (NCI) (47) CSL Behring (38) Octapharma (35) Grifols (33)